- Home
- RVPHW vs VLYPO Comparison
RVPHW vs VLYPO Comparison
Compare RVPHW & VLYPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPHW
- VLYPO
- Stock Information
- Founded
- RVPHW N/A
- VLYPO N/A
- Country
- RVPHW United States
- VLYPO United States
- Employees
- RVPHW 15
- VLYPO 3749
- Industry
- RVPHW Biotechnology: Pharmaceutical Preparations
- VLYPO Major Banks
- Sector
- RVPHW Health Care
- VLYPO Finance
- Exchange
- RVPHW Nasdaq
- VLYPO Nasdaq
- Market Cap
- RVPHW N/A
- VLYPO N/A
- IPO Year
- RVPHW 2018
- VLYPO N/A
- Fundamental
- Price
- RVPHW $0.14
- VLYPO $24.92
- Analyst Decision
- RVPHW
- VLYPO
- Analyst Count
- RVPHW 0
- VLYPO 0
- Target Price
- RVPHW N/A
- VLYPO N/A
- AVG Volume (30 Days)
- RVPHW N/A
- VLYPO N/A
- Earning Date
- RVPHW N/A
- VLYPO N/A
- Dividend Yield
- RVPHW N/A
- VLYPO N/A
- EPS Growth
- RVPHW N/A
- VLYPO N/A
- EPS
- RVPHW N/A
- VLYPO N/A
- Revenue
- RVPHW N/A
- VLYPO N/A
- Revenue This Year
- RVPHW N/A
- VLYPO N/A
- Revenue Next Year
- RVPHW N/A
- VLYPO N/A
- P/E Ratio
- RVPHW N/A
- VLYPO N/A
- Revenue Growth
- RVPHW N/A
- VLYPO N/A
- 52 Week Low
- RVPHW N/A
- VLYPO N/A
- 52 Week High
- RVPHW N/A
- VLYPO N/A
- Technical
- Relative Strength Index (RSI)
- RVPHW N/A
- VLYPO 40.64
- Support Level
- RVPHW N/A
- VLYPO $24.57
- Resistance Level
- RVPHW N/A
- VLYPO $25.52
- Average True Range (ATR)
- RVPHW 0.00
- VLYPO 0.19
- MACD
- RVPHW 0.00
- VLYPO -0.06
- Stochastic Oscillator
- RVPHW 0.00
- VLYPO 36.84
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Valley National Bancorp is a bank holding company whose principal wholly-owned subsidiary is Valley National Bank. It provides a full range of commercial, retail, and trust and investment services largely through its offices and ATM network throughout northern and central New Jersey, New York City Long Island, Florida, and Alabama. The segments of the group are commercial lending, consumer lending, investment management, and corporate and other adjustments, of which key interest income is derived from the commercial lending segment. In recent years, the company has focused on acquiring companies that operate outside of traditional banking and has emphasized wealth and capital management.